var data={"title":"Fresh frozen plasma (FFP), solvent/detergent treated: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fresh frozen plasma (FFP), solvent/detergent treated: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/538610?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225140\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Octaplas</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225142\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Blood Product Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225347\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> Administer based on ABO-blood compatibility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or when undergoing cardiac surgery or liver transplantation:</b> IV: Initial: 10 to 15 mL/kg. <b>Note:</b> Initial dose should increase plasma coagulation factors by ~15% to 25%; if hemostasis is not attained, may use higher doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP):</b> IV: 40 to 60 mL/kg. <b>Note:</b> Dose amount corresponds to 1 to 1.5 plasma volumes. Completely replace plasma volume removed during plasmapheresis with pooled plasma (human).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990357\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987754\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225348\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225141\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225351\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Visually inspect for particulate matter or discoloration prior to administration. Do not use if turbid. Administer IV at a rate &le;1 mL/kg/minute using an infusion set with a filter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225146\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or when undergoing cardiac surgery or liver transplantation; plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225139\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Octaplas may be confused with Octaplex</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225173\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (&ge;1%), paresthesia (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (&ge;1%), urticaria (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, alkalosis, anaphylactic shock, anaphylactoid reaction, bronchospasm, chest discomfort, chest pain, chills, dyspnea, erythema, fever, hypersensitivity reaction, hypotension (severe), hypervolemia, increased fibrinolysis, passive immunization, pulmonary edema, respiratory failure, skin rash, tachycardia, tachypnea, thromboembolism, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225151\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of hypersensitivity to pooled plasma (human), fresh frozen plasma (FFP), or to plasma-derived products including any plasma protein; IgA deficiency; severe protein S deficiency </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225171\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Citrate toxicity: Hypocalcemia and associated symptoms (eg, fatigue, paresthesia, muscle spasm) due to citrate toxicity may occur with infusion rates &gt;1 mL/kg/minute (or 0.02 to 0.025 mmol citrate/kg/minute) especially in patients with hepatic dysfunction. If administering calcium gluconate to minimize citrate toxicity, administer calcium gluconate via another vein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperfibrinolysis: Because of reduced concentrations of alpha-2 antiplasmin, a physiologic inhibitor of t-PA-induced fibrinolysis, in solvent-detergent treated plasma, an increase in the incidence of hyperfibrinolysis has been observed in patients undergoing liver transplantation; monitor for signs of excessive bleeding (de Jonge, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity (including anaphylactoid or allergic reactions) has been reported. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypervolemia: High infusion rates may induce hypervolemia and subsequent pulmonary edema or heart failure. Monitor patients for signs and symptoms of pulmonary edema or heart failure and begin appropriate therapy if necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombosis: Solvent-detergent treated plasma contains low concentrations of protein S; during therapy, monitor for signs and symptoms of thrombosis in patients at risk. Use is contraindicated in patients with severe protein S deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transfusion reactions: Administer pooled plasma (human) based on ABO compatibility; transfusion reactions may occur if ABO is mismatched.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may be at increased risk of citrate toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease, including a theoretical risk of Creutzfeldt-Jakob disease transmission. Infections thought to be transmitted by this product should be reported to the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265547\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265545\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=88325&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225147\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225148\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Treatment of thrombotic thrombocytopenic purpura (TTP) during pregnancy is generally the same as in nonpregnant women (Hunt, 2013; McCrae, 2010; Scully, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225150\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Immunoglobulins, albumin and other components of pooled human plasma are endogenous components of breast milk (IOM 1991). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225355\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor response including activated partial thromboplastin time (aPTT), prothrombin time (PT), and/or specific coagulation factors. Monitor for signs of excessive bleeding (patients undergoing liver transplantation); signs and symptoms of pulmonary edema or heart failure; signs and symptoms of thrombosis (in patients at risk).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16225343\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replaces human plasma proteins (eg, albumin, immunoglobulin and other globulins, coagulation factors, complement proteins, protease inhibitors)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059523\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Octaplas (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    de Jonge J, Groenland TH, Metselaar HJ, et al, &ldquo;Fibrinolysis During Liver Transplantation is Enhanced by Using Solvent/Detergent Virus-Inactivated Plasma (ESDEP&reg;),&rdquo; <i>Anesth Analg</i>, 2002, 94(5):1127-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/11973173/pubmed\" target=\"_blank\" id=\"11973173\">11973173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doyle S, O&rsquo;Brien P, Murphy K, et al, &ldquo;Coagulation Factor Content of Solvent/Detergent Plasma Compared with Fresh Frozen Plasma,&rdquo; <i>Blood Coagul Fibrinolysis</i>, 2003, 14(30):283-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/12695752/pubmed\" target=\"_blank\" id=\"12695752\">12695752</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt BJ, Thomas-Dewing RR, Bramham K, et al, &quot;Preventing Maternal Deaths Due to Acquired Thrombotic Thrombocytopenic Purpura,&quot; <i>J Obstet Gynaecol Res</i>, 2013, 9(1):347-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/22690700/pubmed\" target=\"_blank\" id=\"22690700\">22690700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), &ldquo;Nutrition During Lactation,&rdquo; National Academy of Sciences Washington, DC: National Academy Press, 1991. Available at <a href=\"http://www.nap.edu/\" target=\"_blank\">http://www.nap.edu</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jilma-Stohlawetz P, Kursten FW, Horvath M, et al, &ldquo;Recovery, Safety, and Tolerability of a Solvent/Detergent-Treated and Prion-Safeguarded Transfusion Plasma in a Randomized, Crossover, Clinical Trial In Healthy Volunteers,&rdquo; <i>Transfusion</i>, 2013 [epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/23320451/pubmed\" target=\"_blank\" id=\"23320451\">23320451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrae KR, &quot;Thrombocytopenia in Pregnancy,&quot; <i>Hematology Am Soc Hematol Educ Program</i>, 2010,  2010:397-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/21239825/pubmed\" target=\"_blank\" id=\"21239825\">21239825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Octaplas (pooled plasma [human]) [prescribing information]. Hoboken, NJ: Octapharma USA Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scully M, Hunt BJ, Benjamin S, et al, &quot;British Committee for Standards in Haematology. Guidelines on the Diagnosis and Management of Thrombotic Thrombocytopenic Purpura and Other Thrombotic Microangiopathies,&quot; <i>Br J Haematol</i>,  2012, 158(3):323-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/22624596/pubmed\" target=\"_blank\" id=\"22624596\">22624596</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 88325 Version 36.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F16225140\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F16225142\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F16225347\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990357\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987754\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F16225348\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F16225141\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16225351\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F16225146\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F16225139\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16225173\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F16225151\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F16225171\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F16265547\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F16265545\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F16225147\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16225148\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16225150\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F16225355\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16225343\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059523\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/88325|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}